Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 4249.23%.

  • Insight Molecular Diagnostics' EBITDA Margin rose 75029400.0% to 4249.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 1392.91%, marking a year-over-year increase of 47556100.0%. This contributed to the annual value of 3245.14% for FY2024, which is 15727500.0% down from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' EBITDA Margin stood at 4249.23%, which was up 75029400.0% from 1900.0% recorded in Q2 2025.
  • Insight Molecular Diagnostics' EBITDA Margin's 5-year high stood at 1969.7% during Q1 2023, with a 5-year trough of 11752.17% in Q3 2024.
  • Its 5-year average for EBITDA Margin is 2575.16%, with a median of 1791.36% in 2023.
  • In the last 5 years, Insight Molecular Diagnostics' EBITDA Margin surged by 516830700bps in 2021 and then plummeted by -102339900bps in 2024.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' EBITDA Margin stood at 994.15% in 2021, then tumbled by -328bps to 4251.09% in 2022, then dropped by -21bps to 5152.55% in 2023, then soared by 56bps to 2262.92% in 2024, then plummeted by -88bps to 4249.23% in 2025.
  • Its EBITDA Margin stands at 4249.23% for Q3 2025, versus 1900.0% for Q2 2025 and 318.01% for Q1 2025.